EdgeScore

MRNA · Nasdaq · Financial statements

Moderna, Inc.: cash-flow calculator

A discounted cash flow model turns assumptions about future free cash flow into a single amount today. Here the assumptions are yours: the page shows what they add up to, and, the other way round, what yearly growth a share price takes for granted.

Free cash flow
-$2.1B
FY 2025
5-year average
$1.6B
FY 2021–2025
Net debt
-$2.0B
FY 2025
Diluted shares
389.0M
FY 2025

A cash-flow model does not fit these figures well

  • Free cash flow was negative in 2025. Growing a negative number gives a negative value, so the latest year is no base for this model.

You can still enter your own starting free cash flow below, for example what you expect once heavy investment ends. That is your assumption, not a figure from the reports.

Your assumptions

money in USD
Starting free cash flow

Operating cash flow minus capital expenditure, from the annual reports.

%
%

Growth usually slows as a company gets bigger.

%

For ever, so it is usually kept at or below long-run growth of the economy, often 0–3%.

%

The yearly return you require: a risk-free rate plus a premium for risk. Higher means later cash counts for less.

M USD

From the FY 2025 balance sheet. Negative means more cash than debt.

M

Weighted average, diluted, FY 2025.

USD

EdgeScore has no licensed price feed for US shares yet. Type the current share price yourself.

Present value per share, with your assumptions

75.22 USD

Starting from 1.59B USD of free cash flow, growing 5.0% a year for five years, 3.0% for the next five and 2.0% after that, all discounted at 9.0%.

Years 1–10, discounted
12.73B
After year 10, discounted
14.52B
Minus net debt
2.01B
For shareholders
29.26B
Divided by shares
389.0M

What the price implies

Enter a share price to see the growth it implies.

  • Your assumption, years 1–55.0%
  • Revenue, FY 2020–202519.3%
  • Revenue, FY 2022–2025-53.4%
Past growth is the compound yearly change between the fiscal years shown, from the annual reports. The past does not set the future; the comparison only shows how the price's assumption sits against what the company has done.

Sensitivity: value per share

Rows: terminal growth. Columns: discount rate. Other assumptions as entered, values in USD.

g \ r7%8%9%10%11%
1.0%93.0880.0170.2362.6556.60
1.5%98.0883.3472.5664.3357.84
2.0%104.0787.2375.2266.2259.23
2.5%111.4091.8378.2868.3660.78
3.0%120.5797.3481.8670.8162.52

“—”: terminal growth at or above the discount rate has no finite answer.

Year by year
YearGrowthFree cash flowDiscount factorDiscounted
15.0%1.67B0.9171.54B
25.0%1.76B0.8421.48B
35.0%1.85B0.7721.43B
45.0%1.94B0.7081.37B
55.0%2.03B0.6501.32B
63.0%2.10B0.5961.25B
73.0%2.16B0.5471.18B
83.0%2.22B0.5021.12B
93.0%2.29B0.4601.05B
103.0%2.36B0.422996.5M
After 102.0%34.37B0.42214.52B

Terminal value = free cash flow in year 10 × (1 + terminal growth) ÷ (discount rate − terminal growth). Amounts in millions of USD.

Where the starting figures come from

Operating cash flow and free cash flow

Operating cash flow 2017: -$331MFree cash flow 2017: -$390M2017Operating cash flow 2018: -$331MFree cash flow 2018: -$437M2018Operating cash flow 2019: -$459MFree cash flow 2019: -$491M2019Operating cash flow 2020: $2.0BFree cash flow 2020: $2.0B2020Operating cash flow 2021: $13.6BFree cash flow 2021: $13.3B2021Operating cash flow 2022: $5.0BFree cash flow 2022: $4.6B2022Operating cash flow 2023: -$3.1BFree cash flow 2023: -$3.8B2023Operating cash flow 2024: -$3.0BFree cash flow 2024: -$4.1B2024Operating cash flow 2025: -$1.9BFree cash flow 2025: -$2.1B2025
Operating cash flowFree cash flow
FYRevenueOp. cash flowCapexFree cash flow
2025$1.9B-$1.9B$192M-$2.1B
2024$3.2B-$3.0B$1.1B-$4.1B
2023$6.8B-$3.1B$707M-$3.8B
2022$19.3B$5.0B$400M$4.6B
2021$18.5B$13.6B$284M$13.3B
2020$803M$2.0B$68.0M$2.0B
2019$60.2M-$459M$32.0M-$491M
2018$135M-$331M$106M-$437M
2017$206M-$331M$58.4M-$390M

Free cash flow = operating cash flow − capital expenditure. Source: SEC EDGAR, annual reports.

How it works: free cash flow (operating cash flow minus capital expenditure) grows at your stage 1 rate for years 1–5 and your stage 2 rate for years 6–10; after that, a terminal value assumes your terminal growth for ever. Each year is discounted at your rate, net debt (financial debt minus cash, latest balance sheet) is subtracted and the total is divided by diluted shares. The reverse calculation finds, by bisection, the stage 1 growth at which this equals the share price. Operating cash flow is after interest, so subtracting net debt as well is a simplification you can switch off.

The output is arithmetic on your inputs. It is not an EdgeScore estimate of what the shares are worth and not a price target. Figures: SEC EDGAR, annual reports, with the fiscal year shown next to each one.

For information and education only, not investment advice. Data may contain errors.